ICON plc (NASDAQ:ICLR)
, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of the ICOLabs™ Medical Review Application (IMRA) an innovative web based laboratory application that enables more efficient use of medical monitoring time.
The application is ICON’s latest innovation in the drive to expedite the medical management of study subjects. IMRA trends and graphs real-time laboratory values enabling physicians and medical monitors to respond faster to important safety signals earlier in the development process.
Tom O’Leary, President, ICON Central Laboratories, commented: “IMRA satisfies an important need in clinical trials by reducing data review times, which in turn, improves the management of study subjects and enables physicians to expedite the medical management of clinically significant findings.” He continued: “By automating a currently labour intensive process, we can drive down development costs for sponsors while offering 24/7, global access to the latest laboratory data, including detailed analysis of potential trends, signals, alerts and patient-specific data.”
IMRA was developed by ICON physicians specifically for use by fellow physicians, so the application is easy to use and displays data in intuitive ways. On average, the client data within the application is no more than a few hours old, allowing for real-time evaluation of trends, signals and alerts. Additional features of the application include up-to-date alert overviews, intuitive data trending, detailed subject profiling and comprehensive data export tools.
Notes to Editors:
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently employs over 7,300 employees, operating from 71 locations in 39 countries.